clinical considerations when integrating cdk4/6 inhibitors
Published 3 years ago • 9 plays • Length 4:13Download video MP4
Download video MP3
Similar videos
-
5:34
considerations for treating patients with cdk4/6 inhibitors
-
5:34
considerations for treating patients with cdk4/6 inhibitors
-
8:04
key takeaways from esmo: cdk4/6 inhibitors for metastatic hr /her2- breast cancer
-
7:03
updates on cdk4/6 inhibitor therapy
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
5:16
the clinical potential of cdk4/6 inhibitors
-
3:12
educating patients and staff on using cdk4/6 inhibitors
-
3:41
updates on cdk 4/6 inhibitors in metastatic breast cancer
-
5:34
considerations for treating patients with cdk4/6 inhibitors
-
1:22
dr. rugo on resistance to cdk4/6 inhibitors in hr breast cancer
-
1:51
reflecting on the use of cdk4/6 inhibitors in hr breast cancer
-
9:18
clinical experience: cdk4/6 inhibitors in breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
5:13
evidence-based use of cdk 4/6 inhibitors in breast cancer
-
4:56
interferon-response gene signatures and resistance to cdk 4/6 inhibitors in breast cancer
-
7:46
practical considerations in integrating her2 biosimilars in clinical practice
-
3:57
cdk 4/6 inhibitor as first-line therapy for advanced breast cancer
-
6:58
new data on cdk 4/6 inhibitors: an update from sabcs 2016
-
4:24
new concepts in cdk4/6 inhibitor therapy for breast cancer